• Designing a Learning and Performance Program in Tissue and Organ Banking

    13 April, 2017 David Hofstetter, Manager, Learning and Development, New England Organ Bank

    Keeping up with the changes and the training in tissue and organ banking is an ongoing process. We know what works well and what doesn't. We know with a field-based staff that classroom training is difficult to pull off when trying to coordinate everyone's schedules and of course working around the case load. What we have found is that online learning or on-demand learning does work. This allows all of the staff to access training when and where they need it. We currently offer the following typ

    Full story
  • PFDA, Community Meets to Discuss Priorities Article

    13 April, 2017 MasterControl

    Reviews issues discussed during a recent meeting of FDA and blood community representatives where the two groups presented and reviewed issues important to their operations.On Oct 04, 2007, Food and Drug Administration (FDA) staff met with AABB’s FDA Liaison Committee in Bethesda, MD, to discuss topics of mutual concern in the areas of donor and patient safety. The committee includes liaisons from AABB, the American Red Cross (ARC), America’s Blood Centers (ABC), Advanced Medic

    Full story
  • What To Expect After an FDA Inspection

    13 April, 2017 MasterControl

    From blood supply to vaccines — blood establishments and biologics companies handle complex products that are fundamentally important to human life. It is no wonder that the industry faces some of the toughest regulations and standards today.

    Full story
  • Four Things You Need to Know About FDA's Guidance for Tissue Establishments

    13 April, 2017 MasterControl

    FDA Reminds Manufacturers About Their GTP Responsibilities

    Full story
  • FDA Guidance Pertaining to Certain HCT/Ps: Three Recommended Actions

    13 April, 2017 MasterControl

    FDA Issues HCT/P Guidance

    Full story
  • Increasing Efficiency Through Lean Principles

    13 April, 2017 Rob Carpenter, Product Manager, Customer Relationship Manager and Blood and Biologics Expert, MasterControl, Inc.

    In today's economy many not-for-profit organizations have seen reserves eviscerated due to the stock market tumble. While the stock market has started to rebound, many not-for-profit agencies have also taken a hit on the philanthropic side. Donors are not able to be as generous as they have been in the past. The reserves that not-for-profits have been able to rely on to supplement operating funds are not there anymore. This has forced many organizations to look for other ways to reduce costs. W

    Full story
  • ISTB 128 Sets Industry Safety Standard

    13 April, 2017 Dr. Michael Strong, former Vice-President of Research and Development at Genetic Systems and former Director of Laboratories and Chief Operating Officer at the Puget Sound Blood Center

    The key to satisfying these requirements lies in standardization: globally unique identifiers for products, standardized terminology and a means to convey information electronically that is recognized by computer systems throughout the world. Towards this end, ISBT 128 had been developed.

    Full story
  • Site Selection: Don’t Forget About the Study Drug

    13 April, 2017 by Laurie Meehan, Social Media Manager, Polaris Compliance Consultants, Inc.

    As a sponsor or CRO, you understand the importance of a thorough site selection process. A site needs to be able to meet enrollment targets and timeframes, protect the rights and safety of study participants, execute the protocol, deliver quality data, and maintain GCP compliance. That’s what your site feasibility surveys and pre-study visits are designed to evaluate. And as you’re assessing a site’s abilities, the site is conducting its own feasibility process. They’re mining their patient data

    Full story
  • Top 5 Takeaways from MedTech Intelligence’s Medical Device Cybersecurity Conference

    11 April, 2017 David Jensen, Staff Writer, MasterControl

    I recently attended a conference on Medical Device Cybersecurity hosted by MedTech Intelligence held March 23-24, in Washington, DC. It’s evident that cybersecurity is an important concept as attendance, both in-person and remote, was high. Conference organizers lined up a powerhouse group of presenters who are all entrenched in the technology, cybersecurity, legal and regulatory compliance industries.

    Full story
  • 4 Rules for Building an eClinical Qualification Framework

    6 April, 2017 by Rob Sims, Marketing Programs Manager, UL

    As clinical trials continue to expand globally, technology plays a critical role in maintaining data integrity and at the same time accelerating study start-up. Consider a study management team that must travel globally to hold investigator meetings. Travel now takes up a much greater portion of the study management team’s time and energy.  That’s why study teams have turned to eClinical technology to reduce this effort – from preclinical R&D and regulatory communication to packaging/di

    Full story
  • How to Practice Quality Management in Your Personal Life

    4 April, 2017 Paul Sanderson, Solutions Consultants Manager, MasterControl

    “Quality management” is one of those terms that sounds so simple and esoteric at the same time, like DNA or free cash flow. I’m pretty sure I know what those terms mean until I start explaining them to someone. 

    Full story
  • 5 Warning Signs of Diminishing Supplier Quality

    30 March, 2017 David Butcher, Staff Writer, MasterControl

    supplier’s quality system doing what it’s supposed to be doing? Would you know if it weren’t? How would you know if there were flaws in your supplier’s quality processes before the problems get worse? These are the questions MasterControl’s Terrance Holbrook attempts to answer for medical device manufacturers in a recently published post on MDDI’s Device Talk blog.

    Full story
  • When You Find Yourself Between a Rock and a Hard Place

    27 March, 2017 Beth Pedersen, Staff Writer, MasterControl

    We all have those days where everything that can go wrong, does. Where it seems the entire universe is working against you, testing your patience, your determination and your will to carry on. But in the scheme of things, are these so-called bad days really

    Full story
  • FDA Guidance Answers Questions Regarding Data Integrity

    23 March, 2017 by David Jensen, Staff Writer, MasterControl

    An alarming increase in CGMP violations involving data integrity has come to the attention of FDA. To spotlight this issue, the regulatory watchdog has drafted a question-and-answer-based guidance, “

    Full story
  • The Most Important Four-Letter Words in ISO 9001:2015

    21 March, 2017 by Christine Park, Consultant, Christine Park & Associates

    Most organizations are well under way with the transition to the new ISO 9001:2015.  As such you should be very familiar with the emphasis on two four-letter words found throughout the document ….

    Full story
  • FDA Eager to be Innovative Partner with Expedited Access Pathway

    16 March, 2017 David Jensen, Staff Writer, MasterControl

    Part of FDA’s prime directive is to assure the safety, effectiveness and quality of biological products and medical devices. So the notion of FDA endorsing the acceleration of product development might raise some eyebrows. However, FDA officials and industry experts alike seem to agree that with some patients waiting is not the hardest part, it’s actually not an option.

    Full story
  • The Inner Game of Continuous Improvement

    14 March, 2017 by Jon Miller, Co-founder and Partner, Gemba Academy

    by Tim Gallwey for helping him overcome anxiety and self-doubt, and to keep winning. I read the book looking for parallels and general lessons that could be applied to workplace performance and continuous improvement, and was not disappointed. Here is a summary of what I learned about what I will call “the inner game of continuous improvement.”

    Full story
  • Brave New World: The Mutual Recognition of CGMP Inspections

    9 March, 2017 by Mark I. Schwartz, Director, Hyman, Phelps & McNamara PC

    Last week, the United States and the European Union agreed to recognize each other’s drug cGMP inspections. The agreement reached (see

    Full story